Literature DB >> 28975266

FDA Approval of Tisagenlecleucel: Promise and Complexities of a $475 000 Cancer Drug.

Peter B Bach1, Sergio A Giralt1, Leonard B Saltz1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28975266     DOI： 10.1001/jama.2017.15218

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  42 in total

1.  Flow Cytometric Monitoring for Residual Disease in B Lymphoblastic Leukemia Post T Cell Engaging Targeted Therapies.

Authors:  Sindhu Cherian; Maryalice Stetler-Stevenson
Journal:  Curr Protoc Cytom       Date:  2018-09-13

Review 2.  The Therapeutic Potential of Mesenchymal Stromal Cells in the Treatment of Chemotherapy-Induced Tissue Damage.

Authors:  Alexander Rühle; Ramon Lopez Perez; Bingwen Zou; Anca-Ligia Grosu; Peter E Huber; Nils H Nicolay
Journal:  Stem Cell Rev Rep       Date:  2019-06       Impact factor: 5.739

Review 3.  Biological Products: Cellular Therapy and FDA Approved Products.

Authors:  Ali Golchin; Tahereh Zarnoosheh Farahany
Journal:  Stem Cell Rev Rep       Date:  2019-04       Impact factor: 5.739

4.  Recalibrating Health Technology Assessment Methods for Cell and Gene Therapies.

Authors:  Aris Angelis; Huseyin Naci; Allan Hackshaw
Journal:  Pharmacoeconomics       Date:  2020-12       Impact factor: 4.981

Review 5.  Building a CAR Garage: Preparing for the Delivery of Commercial CAR T Cell Products at Memorial Sloan Kettering Cancer Center.

Authors:  Karlo Perica; Kevin J Curran; Renier J Brentjens; Sergio A Giralt
Journal:  Biol Blood Marrow Transplant       Date:  2018-03-01       Impact factor: 5.742

6.  Synthetic biology: Reframing cell therapy for cancer.

Authors:  Taylor B Dolberg; Patrick S Donahue; Joshua N Leonard
Journal:  Nat Chem Biol       Date:  2018-02-14       Impact factor: 15.040

7.  Highly Priced Gene Therapies: A Wake-Up Call for Early Price Regulation.

Authors:  Feng Xie
Journal:  Pharmacoeconomics       Date:  2018-08       Impact factor: 4.981

8.  Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.

Authors:  Reith R Sarkar; Nicholas J Gloude; Deborah Schiff; James D Murphy
Journal:  J Natl Cancer Inst       Date:  2019-07-01       Impact factor: 13.506

9.  The First Year of HemaSphere and Many More to Come.

Authors:  Andreas Engert; Jan Cools
Journal:  Hemasphere       Date:  2018-11-29

Review 10.  Immune-related Adverse Events in Cancer Patients.

Authors:  Daniel J Pallin; Christopher W Baugh; Michael A Postow; Jeffrey M Caterino; Timothy B Erickson; Gary H Lyman
Journal:  Acad Emerg Med       Date:  2018-05-25       Impact factor: 3.451
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.